A Phase 2 Trial of Darolutamide as a Prostate-Specific Membrane Antigen (PSMA) Expression Enhancer in Patients With Localized Prostate Cancer
Latest Information Update: 05 Mar 2024
At a glance
- Drugs Darolutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Pharmacokinetics
- Acronyms Daro-PET
Most Recent Events
- 27 Jan 2024 According to Trial design presented at the 2024 Genitourinary Cancers Symposium, as of September 20th, 1 patient was included in the study
- 27 Jan 2024 Trial design presented at the 2024 Genitourinary Cancers Symposium
- 03 Aug 2023 Status changed from not yet recruiting to recruiting.